Organization | Inno.N

Inno.N Report issue

For profit Phase 1 Phase 3 Phase 4

Founded: Seoul Korea, Republic of (1984)

Organization Overview

First Clinical Trial

2020

NCT04297865

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

HK inno.N Corporation

Active Ingredients

Drugs in Phase 4 Trials (2)

lansoprazole (prevacid) (2 trials)

tegoprazan (6 trials)

Drugs in Phase 3 Trials (2)

in-c006 (2 trials)

rpn301 (1 trial)

Drugs in Phase 1 Trials (15)

aceclofenac (1 trial)

celecoxib (celebrex) (1 trial)

cj-15314 (1 trial)

ginseng (1 trial)

in-a001 (1 trial)

in-b001 (1 trial)

in-b009 (1 trial)

in-c004 (2 trials)

in-c005 (2 trials)

ino-a002 (1 trial)

naproxen (naprosyn) (1 trial)

netupitant (Akynzeo) (1 trial)

palonosetron (aloxi) (1 trial)

tacrolimus (prograf) (1 trial)

telmisartan (micardis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Foot-and-Mouth Disease (Phase 1)

Hand, Foot and Mouth Disease (Phase 1)

Liver Diseases (Phase 1)

Mouth Diseases (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 20
# of Trial APIs: 19